US OptionsDetailed Quotes
AKBA250516P5000
- 0.00
- 0.000.00%
15min DelayTrading May 15 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover1105.05%IV-98.41%PremiumMay 16, 2025Expiry Date2.48Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8049Delta0.1847Gamma1.05Leverage Ratio-0.1250Theta-0.0001Rho-0.85Eff Leverage0.0004Vega
Akebia Therapeutics Stock Discussion
•Revenues: Total revenues were $57.3 million in the first quarter of 2025 as compared to $32.6 million in the first quarter of 2024, driven by initial sales of Vafseo in the U.S. and an increase in sales of Auryxia.
▪Vafseo net product revenues were $12.0 million in the first quarter of 2025. Vafseo was launched into the U.S. market in the first quarter of 2025.
▪Auryxia net product revenues were $43.8 million in the first quarter...
Major Win for Akebia: EMA Committee Recommends Novel Dual-Action Kidney Disease Treatment
Akebia Therapeutics: Ec Will Review Chmp Recommendation, Final Decision Expected in About Two Months
No comment yet